Clindamycin

C difficile risk
High
Oral Bioavailability
Excellent

Dosing

IV/IM 10-40mg/kg/DAY divided q6-8h. Max: 2700mg/DAY.PO 10-40 mg/kg/DAY divided q6-8h. Max: 2700 mg/DAY.

0 - 2 kg2+ kgIV 5mg/kg/DOSE q12h.IV 5mg/kg/DOSE q8h.

0 - 2 kg2+ kgIV 5mg/kg/DOSE q8-12hIV 5mg/kg/DOSE q6h

Use caution with severe hepatic impairment.

General Information

Anaerobic infections above the diaphragm, especially dental infection.

Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta lactam for reducing toxin production.

Skin & soft tissue infections involving susceptible MRSA.

Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

For decreasing toxin production in toxic shock syndrome.

Monitor for diarrhea, CBC, hepatic & renal function.

If severe diarrhea, consider C.diff infection.

Allergy (immediate & delayed), GI upset, diarrhea, cytopenia, abnormal liver enzymes, pseudomembranous colitis.

Some preparations of Clindamycin injection contain benzyl alcohol, which has caused gasping syndrome in neonates.

Antimicrobial class: Lincosamide

Average serum half life:

  • Premature neonates: 8.7 hours

  • Full term neonates: 3.6 hours.

  • Infants 1 month to 1 year: 3 hours.

  • Children and Adults: 2-3 hours

Route of Elimination: Mostly hepatic metabolism. 10% of an oral dose excreted in urine and 3.6% excreted in feces as active drug and metabolites.